Development of therapy approach in Patient with Chronic Granulocity Leukemia: Case Report

Chronic granulocytic leukemia (CGL), Ph + is a chronic myeloproliferative disorder, which, due to its specificity for many decades, has attracted the attention of researchers of numerous specialties. This disease was among the first malignant haemopathies that received their “ID card” since molecular analyzes precisely defined the basic pathological substrate, that is, the origin of the disease. Over the past decades we have witnessed the evolution of the therapeutic approach in the treatment of CGL from oral cystostatic therapy, radiotherapy, through recombinant interferon alpha (IFN-alpha), haematopoeza stem cell transplantation, to the targeted molecular therapy of the tyrosine kinase inhibitor (TKI). In this report we present patient with a diagnosis of CGL, Ph + in the early chronic phase at the age of 13 years based on all relevant analyzes. During the past 26 years, all therapeutic modalities of CGL treatment were applied in patients, according to the time period, concluding with the second generation TKI, resulting in complete remission of diseases with excellent quality of life and identical expectations for the future, as well as in the healthy population.